Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee

• DOI: 10.1007/s12325-016-0331-8
• Publication Date: 2016-05-04T09:26:38Z
• Authors: Jeffrey Rosen; Parag Sancheti; Anke Fierlinger; Faizan Niazi; Herman Johal; Asheesh Bedi
• Keywords: Viscosupplementation

Osteoarthritis (OA), as one of the leading causes disability, decreases quality life for those suffering from disease and creates a substantial financial burden. Intra-articular hyaluronic acid (HA) can provide relief symptoms OA multiple HA products are prescribed. The purpose this study is to examine single payer cost-effectiveness various in treatment knee OA. A economic evaluation was conducted comparing Synvisc® (Sanofi, USA), Durolane® (Bioventus, Hyalgan® (Fidia Pharma Inc., Supartz™ Euflexxa® (Ferring Pharmaceuticals USA). Utility scores were obtained by extracting Western Ontario McMaster Universities Arthritis Index pain, stiffness function randomized controlled trials converting them health utilities index mark 3 scores. cost included injection, injection procedure doctor's visit each required injection. Cost–utility 2015 USD per quality-adjusted years (QALY) saved calculated product, incremental ratios compare effectiveness another conventional care. When compared care, all investigated cost-effective, assuming willingness-to-pay threshold $50,000/QALY gained. product Euflexxa had most favorable cost–utility ratio ($5785.52/QALY) when other brands. present showed several be cost-effective comparison with having cost/QALY gained products. Ferring Pharmaceutics Inc.